Progress in studies on rotavirus vaccine
10.3760/cma.j.cn112866-20200630-00201
- VernacularTitle:轮状病毒疫苗的研究现状
- Author:
Mingwen WANG
1
;
Dandi LI
Author Information
1. 甘肃中医药大学公共卫生学院，兰州 730000
- Keywords:
Rotavirus;
Diarrhea;
Vaccine
- From:
Chinese Journal of Experimental and Clinical Virology
2021;35(3):312-316
- CountryChina
- Language:Chinese
-
Abstract:
Rotavirus is the most important pathogen of severe diarrhea in infants and young children in the world. According to the World Health Organization, about 185 000 children die from rotavirus each year. The related deaths mainly occur in low-income countries in Asia and Africa. Rotavirus infections are common even in areas with better sanitary conditions, indicating that rotavirus has a high transmission capacity. At present, there is no specific treatment for rotavirus diarrhea, only symptomatic treatment is available. Therefore, safe and effective vaccines are of great significance in reducing the incidence and mortality of rotavirus diarrhea. The World Health Organization also recommends that oral rotavirus vaccines should be included in the immunization program of all countries. At present, China’s oral rotavirus vaccine LLR has been on the market in China since 2001. The vaccines available on the market in most countries are Rotarix (RV1) and Rotateq (RV5). The vaccine is useful for preventing diarrhea caused by rotavirus infection. The vaccination to prevent rotavirus disease is very cost-effective. This article reviews the current situation of rotavirus vaccines in order to provide a scientific evidences for the prevention and control of rotavirus.
